跳至主要内容
临床试验/NCT04798690
NCT04798690招募中不适用

Open, Multi-center, Non-interventional, Prospective/ Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Dong-A ST Co., Ltd.1 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2021年2月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
5,000
试验地点
1
主要终点
Long term safety assessed through the adverse events

研究概览

简要总结

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
  • •Children who has official height record at least 6 months prior

排除标准

  • •Children with Epiphyseal closure

研究组 & 干预措施

Growth hormone

Growtropin®-II

结局指标

主要结局

Long term safety assessed through the adverse events

时间窗: Up to 2 years after epiphyseal closure

Number of occurrence of treatment-related adverse events

次要结局

  • Changes in Height SDS(Up to 2 years after epiphyseal closure)
  • The difference between target height and final height(Up to 2 years after epiphyseal closure)
  • Changes in skeletal maturity(Up to 2 years after epiphyseal closure)
  • Changes in IGF-1(Up to 2 years after epiphyseal closure)
  • Changes in BMI SDS(Up to 2 years after epiphyseal closure)
  • Change of annualized height velocity(Up to 2 years after epiphyseal closure)
  • Changes in IGFBP-3(Up to 2 years after epiphyseal closure)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验